April 19, 2010
Oravig buccal tablets approved for oropharyngeal candidiasis
Oravig buccal tablets adhere to the gum and deliver miconazole directly at the local site of infection throughout the day with minimal systemic absorption. Oravig will be available in a 50mg dosage strength as a flavorless, odorless buccal tablet. It is expected to be made available in the third quarter of 2010.
For more information call (201) 802-4000 or visit www.strativapharma.com.